Coherus Biosciences | CHRS - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Akebia Therapeutics 349.66M 12.86M 2026-06
ALKERMES USD 25.92M 5.03M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amarin USD 3K 5K 2024-12
Amgen USD 95.64B 94.98B 2026-06
Baxter International USD 78M 20M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Fujifilm JPY 863M 429M 2026-03
Gilead Sciences USD 247M 7M 2026-06
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
Merck USD 525M 46M 2026-06
Myriad Genetics USD 4.4M 600K 2025-12
Pacira USD 3.62M 77K 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 667M 4M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 7.35M 2.65M 2026-06
Zoetis USD 61M 1000K 2026-06